ArticleJAMA network open2025
Relative Age in School and Initiation of Speech Therapy in Children.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shared and disorder-specific prenatal and perinatal risk factors for neurodevelopmental disorders: a nationwide cohort study.Molecular psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: In most countries, children in the same grade can be up to 12 months apart in age, which represents a considerable relative age difference, particularly in the early years. A relative age effect has been frequently reported in the diagnosis and treatment of attention-deficit/hyperactivity disorder and, more rarely, in the diagnosis of other neurodevelopmental disorders. The relative age effect has never been studied for speech therapy, which is frequently prescribed to treat specific language and learning disorders. Objective: To quantify the association of relative age with the initiation of speech therapy. Design, Setting, and Participants: This cohort study used data from the French National Health Data System and included all children born in France between 2010 and 2016 from September of the year of their 5th birthday until July of the year of their 10th birthday or July 31, 2022 (end of study). Exposure: Children were categorized according to month of birth. Main Outcomes and Measures: Risk of speech therapy initiation was estimated using Cox models adjusted for other known risk factors. Results: In total, 4 188 985 children (mean [SD] age, 5.2 [0.3] years; 50.8% girls) were included. Speech therapy was initiated for 692 086 children (incidence rate, 53.1 per 1000 person-years, 54.5% boys) during a mean (SD) follow-up of 3.1 (1.6) years. Among children of the same schooling level, the risk of initiating speech therapy steadily increased according to quarter and month of birth, with adjusted hazard ratios of 1.51 (95% CI, 1.50-1.52) for children born in the last quarter vs the first quarter and 1.64 (95% CI, 1.62-1.66) for children born in December vs those born in January. The relative age effect observed for speech therapy was of the same magnitude as that observed for methylphenidate in attention-deficit/hyperactivity disorder (positive control outcome). No relative age effect was observed for the initiation of desmopressin for nocturnal enuresis (negative control outcome). Conclusions and Relevance: This cohort study found that among children in the same grade, an age difference of a few months was associated with the frequency of initiation of speech therapy. These findings may be attributable to a mismatch between the expectations of the school system and the relative age and level of maturity of the children or earlier identification of neurodevelopmental disorders in the youngest children in each age group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.